Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that its representatives will participate in the IPAC-RS 2026 Nasal Innovation Forum, scheduled for September 16-17, 2026, in Jersey City, New Jersey. The forum brings together experts in nasal drug development, providing an opportunity for Silo to engage with key opinion leaders as it advances its lead candidate, SPC-15, which utilizes a novel nose-to-brain approach for the targeted delivery of therapeutics to treat post-traumatic stress disorder (PTSD).
The company’s participation is a strategic move to highlight the progress of SPC-15, which has shown promise in preclinical studies. Silo Pharma reported that the SPC-15 formulation and its delivery device met predefined specifications for assay, impurities, pH, and microbiological quality through nine months of stability testing. Additionally, six-month accelerated stability data were consistent and aligned with long-term data, indicating the product’s robustness. These findings are critical for regulatory filings and eventual commercialization.
Eric Weisblum, CEO of Silo Pharma, emphasized the importance of the forum in fostering collaborations and gaining insights into nasal drug development. “The IPAC-RS forum is an ideal venue to discuss the latest advancements in nasal drug delivery, and we look forward to sharing our progress on SPC-15,” he said. The company’s focus on stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases addresses underserved medical needs.
Silo Pharma’s pipeline includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. The company conducts its research in collaboration with leading universities and laboratories, leveraging cutting-edge science to develop innovative therapies.
The selection of SPC-15 for the forum underscores the growing interest in nose-to-brain delivery as a non-invasive method to bypass the blood-brain barrier, potentially improving efficacy and reducing systemic side effects. PTSD affects millions worldwide, and current treatments have limitations, highlighting the need for novel approaches like SPC-15.
Investors and industry observers will be watching Silo Pharma’s presentations at the forum for further details on SPC-15’s development timeline and potential next steps. The company’s participation is part of a broader strategy to gain visibility and validation within the biopharmaceutical community.
For more information about Silo Pharma and its pipeline, visit https://ibn.fm/Dy4qf.
